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www.jacctctabstracts2013.com MONDAY, OCTOBER 28, 2013, 8:00 AM–6:35 PMwall. LV performance was evaluated before (baseline) and immediately after device
implantation by echo.
Results: TCVR was successfully performed in all the animals. Immediately after the
procedure and compared to baseline, LV end-systolic volume was decreased by 54%
(26.98.7 vs. baseline 60.122.2ml, p<0.01) and end-diastolic volume decreased by
34% (54.511.0 vs. baseline 85.620.6ml, p<0.05). Ejection fraction was signiﬁ-
cantly increased by 19.8% (519% vs. baseline 319%, p<0.001) and stroke volume
was preserved (27.56.9 vs. baseline 25.53.8ml, p¼NS).
Conclusions: Minimally invasive thoracoscopically assisted TCVR is feasible and
resulted in signiﬁcant improvement in cardiac volume and ejection fraction in an ovine
infarction model.
TCT-126
First-in-human experience with a novel high-ﬂow percutaneous heart pump
David Kandzari1, Adrian Ebner2, Paul Muller3
1Piedmont Heart Institute, Atlanta, GA, 2Italian Hospital, Asuncion, Paraguay,
3Thoratec Corporation, Pleasanton, CA
Background: High-risk percutaneous coronary interventions (HRPCI) involving
complex disease and/or depressed cardiac function have become increasingly
common. The potential beneﬁt from short-term mechanical circulatory support is
suggested by observations that intraprocedural hemodynamic compromise may impact
completeness of revascularization and contribute to adverse events. We report
outcomes from a First in Human trial using the HeartMate PHP (Percutaneous Heart
Pump) in patients undergoing HRPCI.PHP is a catheter-based axial ﬂow pump
designed to provide partial left ventricular support of up to 5 lpm and is rapidly
delivered percutaneously via typical femoral insertion. The 12F catheter contains
a distal collapsible covered nitinol cannula with an integrated impeller that expands to
24F when deployed across the aortic valve.
Methods: 10 patients with complex coronary disease and reduced LV function (EF from
26% - 34% prior to PCI) underwent elective HRPCI while on PHP support. Device
success, deﬁned as the deployment, use and removal of PHP without device failure; and
periprocedural measures of hemodynamics and cardiac performance were evaluated.
Major adverse safety and efﬁcacy events were assessed during PHP use and at 30 days.
Results: Among the ﬁrst 3 patients, PHP was successfully deployed in all patients
without complications. There was no periprocedural or follow-up echocardiographic
evidence of aortic regurgitation or valve abnormalities. All patients remained hemo-
dynamically stable while on support and all planned target lesions were revascular-
ized. The PHP was successfully removed in all cases and there were no adverse patient
events while on device support through 30 days. (Outcomes on the full patient series
will be presented when complete.)CARDIAC INDEX MAP PCWP
Baseline
On
Support Baseline
On
Support Baseline
On
Support
Pt #1 2.8 3.17 73 65 41 16
Pt #2 2.67 2.45 84 112 11 5
Pt #3 2.3 3.26 97 119 8 9Conclusions: In a First in Human trial involving patients undergoing HRPCI,
hemodynamic support using the HeartMate PHP is feasible and safe.O
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TCT-127
Trans-Auricular Intra-Pericardial Tricuspid Annuloplasty (TRAIPTA)
Toby Rogers1, Kanishka Ratnayaka1, William H. Schenke1, Anthony Z. Faranesh1,
Merdim Sonmez1, Dominique N. Franson1, Robert J. Lederman1
1National Heart Lung and Blood Institute, National Institutes of Health, Bethesda,
MD
Background: Functional tricuspid regurgitation (TR) is clinically signiﬁcant. TR
predicts mortality independent of LVEF, age or pulmonary artery pressure. PersistentJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 Years oTR after mitral valve surgery is an independent poor prognostic sign. Tricuspid valve
repair is usually an adjunct to other surgery. We present TRAIPTA, a novel percu-
taneous treatment of functional TR. We demonstrate pre-clinical feasibility in swine.
Methods: Through the femoral vein and under X-ray guidance, the pericardial space
is accessed by puncture through the right atrial appendage (Panel A). A custom
memory-shape delivery device positions a suture circumferentially in the AV groove
(Panel B) and used to deploy a semi-rigid device to apply direct compression to the
tricuspid annulus. The suture is tightened to achieve the desired degree of annulo-
plasty (Panel C), then secured and cut. The atrial appendage access is closed with an
occluder.Results: In naïve swine, trans-auricular pericardial access was easy and safe. The
TRAIPTA device is consistently delivered to the AV groove, tension can be selec-
tively applied to the tricuspid annulus, and RV geometry interactively altered.
Conclusions: Percutaneous treatment of functional TR is feasible in swine using
TRAIPTA.
TCT-128
Transcatheter Implantation of Self-Expandable Vena Cava Valves for Treatment
of Tricuspid Regurgitation: First-Human-Case Description
Hans R. Figulla1, Torsten Doenst2, Marcus Franz2, Ali Hamadanchi3,
Daniel Kretzschmar3, Alexander Lauten2
1Friedrich-Schiller Universitat, Jena, Germany, 2University Hospital Jena, Jena,
Germany, 3Heart Center of the Friedrich-Schiller-University, Jena, Thuringia
Background: Despite the recent advances in interventional treatment of heart valve
disease, no transcatheter approach is established for severe tricuspid regurgitation
(TR). Single valve implantation into the inferior vena cava (IVC) has been suggested,
which however only partially resolves the hemodynamic sequelae of TR. After
extensive preclinical evaluation, we herein report the ﬁrst human case of bi-caval self-
expanding valve implantation (CAVI) in the superior (SVC) and inferior vena cava.
Methods: CAVI was performed in a 83-year-old patient with severe TR, chronic right
heart failure and congestive hepatopathy. Two self-expanding pericardial valves were
custom-made to ﬁt to the anticipated implantation zones in the caval veins of this
patient. Both devices were implanted under ﬂouroscopy using a 27F-catheter and
deployed at the level of the cavo-atrial junction of the SVC and the IVC. To protect
the hepatic veins from backward ﬂow, the inferior valve was aligned just above the
hepatic vein inﬂow and deployed with the valve protruding into the right atrium (RA).
Results: After deployment and during 3-month follow-up excellent valve function
was observed. The procedure resulted in a marked reduction of the pressure in the
SVC and IVC from 27/14mmHg and 28/15mmHg to 21/7mmHg and 13/6mmHg at 3
month, respectively. After implantation symptoms of right heart failure resolved and
did not recurr during follow-up and synthetic liver function recovered. The patients
physical capacity improved with an increase in distance covered in 6-minute-walk-test
from 20m before implantation to 200m at 3 month.
Conclusions: In this ﬁrst-in-man experience, transcatheter CAVI proved feasible and
resulted in persistent hemodynamic and clinical improvement. Further conﬁrmatory
experience with longer follow-up is required to evaluate the clinical beneﬁt of the
procedure.
TCT-129
Percutaneous Transfemoral Management of Severe Secondary Tricuspid
Regurgitation with Edwards Sapien XT Bioprosthesis in patients with severe
heart failure: ﬁrst in man experience
Michael Laule1, Gert Baumann2, Fabian Knebel2, Wasiem Sanad2, Verena Stangl3,
Karl Stangl4
1Charité University Hospital, berlin, Berlin, 2Charite, Berlin, Berlin, 3Charité, Berlin,
Berlin, 4Charité - Campus Mitte, Berlin, Germany
Background: Severe tricuspid regurgitation (STR) is a common ﬁnal pathway in
advanced stages of heart failure (HF) and associated with increased morbidity and
mortality. The prevalence of moderate to severe TR is 35% in HF patients occurring in
1.6 Mio patients in the US. In advanced TR stages, the surgical risk is prohibitively
high, alternative approaches are therefore required. Here we describe the feasibility as
well as periprocedural and short-term outcomes of a novel ﬁrst-in-man single caval
and dual caval approach for implantation of the Edwards Sapien XT.
Methods: Vena cava inferior (VCI) single valve approach: to guarantee stable
placement we prepared a landing zone by implanting a self-expanding 30/60-mm
Sinus XL Stent in the IVC segment downstream of the RA. To further downsize thef Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013 B41
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Slumen we placed a second, shorter stent in the upper part of the ﬁrst stent. The
Edwards Sapien XT valve mounted on the Novaﬂex delivery system was then
deployed In the dual caval valve approach we implanted a second valve into the vena
cava superior (SVC) as described.
Results: From August 2nd, 2012 to now we treated 6 pts (2 f, 4 m; 5 ICV single, 1
IVC and SVC dual valve) with a FU up to 11 mo. Safety: Periprocedural mortality:
0%; technical success: 100%; VARC 30-day safety endpoint: 0%, valve dysfunction:
0%. Clinical results: 5/6 pts improved by at least 1 NYHA class, in 5/6 pts signs of
right heart congestion decreased, in 2/2 pts with cardiorenal syndromes and terminal
failure renal function improved allowing discontinuation of dialysis. In 6/6 pts hepatic
veins diameters decreased (-34%). Right heart parameters: In msCT measurements
volumes of the anatomical RV decreased (-14,8%), surprisingly, also volumes of the
anatomical RA decreased (-13%). In echo measurements, TAPSE increased from 14,5
to 18,6 cm.
Conclusions: Percutaneous single or dual caval valve implantation with the Edwards
Sapien XT for severe TR is feasible and safe.With all due care at this early stage, this
approach appears to be a new promising interventional tool to improve right heart
hemodynamics and to ameliorate symptoms of right heart failure in advanced stages of
heart failure.
TCT-130
Marrow stromal cell based transcatheter aortic valve implantation – experiences
in a preclinical animal model
Maximilian Y. Emmert1, Volkmar Falk2, Jürg Grünenfelder3, Simon P. Hoerstrup4,
Jacques Scherman1, Benedikt Weber1, Petra Wolint5
1University Hospital Zurich, Zurich, Switzerland, 2University of Zurich, Zürich,
Zürich, 3University Hospital Zürich, Zürich, Zürich, 4University of Zürich, Zürich,
Switzerland, 5Swiss Centre for Regenerative Medicine, Zurich, Switzerland
Background: Transcatheter aortic-valve implantation (TAVI) has rapidly evolved as
an effective treatment alternative for aortic-valve disease. The currently utilized bio-
prostheses are prone functional degeneration. Autologous, stem cell based, tissue-
engineered heart-valves (TEHV) with self-repair capacity have been repeatedly
proposed to overcome these limitations. We summarize our initial experience on
marrow stromal cell based TAVI in an adult sheep model.
Methods: Tri-leaﬂet TEHV generated from synthetic-scaffolds were integrated into
self-expanding Nitinol stents, seeded with autologous marrow-stromal cells. There-
after, in a series of animal experiments, TEHV were transapically delivered into the
descending aorta (n¼3) and the orthotopic aortic-valve position of adult sheep (n¼16)
using different delivery systems including a generic system and the anatomically-
orienting JenaValve transapical TAVI System (JenaValve, Munich/Germany). Follow
up was up to two weeks. Positioning and functionality were assessed by angiography
and echo before the TEHV underwent post-mortem gross examination and histology.
CT scan was used to assess stent positioning.
Results: Transcatheter implantation of TEHV into the descending aorta (n¼3) and
into the orthotopic aortic-valve position (n¼16) was successful in all animals. Fluo-
roscopy and echo conﬁrmed sufﬁcient positioning at the intended delivery site. All
TEHV tolerated the loading-pressure of the systemic-circulation and no acute ruptures
or tears occurred. Animals displayed intact and mobile leaﬂets with an adequate
functionality (mean trans-valvular gradient <10mmHg in all animals). Importantly,
TEHV orthotopically implanted (n¼16) entirely excluded the native aortic leaﬂets and
did not compromise the coronary arteries. Histology was indicative for an early
cellular-remodelling.
Conclusions: We demonstrate transcatheter based TEHV implantation into the aorta
within a one-step intervention. Our data indicate the feasibility to combine the concept
of TEHV and transcatheter delivery representing a key step towards clinical trans-
lation. Long-term functionality proven, a cell based TEHV approach may represent
a next generation heart-valve therapy concept.
TCT-131
Use Of A Novel Echo-ﬂuoroscopy Overlay System For Percutaneous Mitral
Valve Intervention
Sameer Gafoor1, Jennifer Franke1, Stefan C. Bertog1, Simon C. C. Lam1,
Laura Vaskelyte1, Ilona Hofmann1, Horst Sievert1
1CardioVascular Center Frankfurt, Frankfurt, Germany
Background: Percutaneous mitral valve repair requires a close understanding of both
ﬂuoroscopy and periprocedural imaging. Real time 3D transesophageal echocardi-
ography is often used for guidance. We report the use of 3D-echocardiography-
ﬂuoroscopy fusion for mitral valve repair.
Methods: Patients presenting to our center for mitral valve repair had their procedure
performed using an echocardiographic-ﬂuoroscopic overlay system. The EchoNavi-
gator (Philips, Inc) system requires transesophageal echocardiography, which is
registered to ﬂuoroscopy based on probe angle and position. Relevant structures can
be marked on echocardiography and tracked with ﬂuoroscopy. Procedural charac-
teristics of these patients were collected.
Results: Nine patients at our center underwent percutaneous mitral valve repair with
MitraClip (Abbott Vascular, Santa Clara, CA) using a novel 3D-echocardiographic-
ﬂuoroscopic overlay technology (EchoNavigator, Philips Inc.). The EchoNavigator
system was useful for transseptal puncture, understanding mitral valve anatomy,
sheath exchange, clip advancement, and post-deployment visualization.B42 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/ORAL/25 YConclusions: The use of EchoNavigator echo-ﬂuoroscopy overlay system is feasible
and useful in MitraClip intervention.TCT-132
Prospective, Multicenter Tack Optimized Balloon Angioplasty (TOBA) Study for
Femoropopliteal Arteries Using the Tack-IT Endovascular SystemTM
Koen Deloose1, Marianne Brodmann2, Hans M. Gissler3, Dierk Scheinert4,
Marc Bosiers5
1A.Z. St. Blasius Hospital, Dendermonde, Belgium, 2Medical University Hospital
Graz, Graz, Austria, 3Hochrhein-Eggberg Clinic, Bad Säckingen, Germany, 4Park-
Krankenhaus Leipzig, Leipzig, Germany, 5A.Z. Sint-Blasius, Dendermonde, Belgium
Background: We evaluated an alternative method to treat post PTA dissection using
a novel device, The Tack-IT Endovascular System, by Intact Vascular, Wayne, PA,
indicated for tissue apposition to optimize angioplasty results in peripheral arteries.
The Tack is a circumferential, self-expanding Nitinol device 6mm in length. The Tack
is designed to provide focal treatment only where needed. The Tack accommodates
arterial diameters between 2.5 - 5.5mm and has low outward force onto the arterial
wall. Up to 8 Tacks can be used to treat lesions up to 100mm in length.
Methods: One hundred thirty eight subjects were enrolled in the Tack Optimized
Balloon Angioplasty (TOBA) study. The lesion length was <100mm. The primary
endpoints were Safety and Device Technical Success at 30 days. Safety included
major device-related adverse event(s) including device embolization, emergency
surgical revascularization, index limb amputation (above the ankle) or clinically-
driven TLR at 30 days. Device Technical Success was the ability of the Tack to
resolve post-PTA dissection demonstrated that the artery at the Tack(s) location
remained patent at the end of the procedure (<30 % residual stenosis). Subjects were
followed 1, 6 and 12 months.
Results: FULL STUDY RESULTS WILL BE AVAILABLE BY TCT. Ninety one of
the 138 subjects are enrolled. The mean age was 70 with 62% males. The co-
morbidities included 65% with diabetes, 62% smokers, 73% hypertension and 64%
elevated cholesterol. Eighty four (84) subjects had a sub-optimal PTA, 5 optimal PTA
and 2 did not meet the I/E criteria. The mean lesion length was 47.5mm and RVD
5.40mm. At 30 days (primary endpoint) there were no major device-related adverse
events, emergency surgical revascularizations, no index limb amputations. One (1)
clinically-driven TLR (1.2%) reported. One hundred percent (100%) technical success
was achieved in all the treated lesions and all (292) Tacks were successfully placed.
Conclusions: The Tack is designed to create tissue apposition with minimal amount
of metal and low outward force to allow natural arterial ﬂexibility and low neointimal
response. Long term clinical evidence will conﬁrm the clinical beneﬁts of this novel
technology.
TCT-133
THEMULTILAYER FLOWMODULATOR STENT FOR THE TREATMENT
OF PERIPHERAL AND VISCERAL ANEURYSMS.
Michel C. Henry1, Amira Benjelloun2, Isabelle P. henry3, Antonios Polydorou4
1Cabinet de cardiologie, nancy, France, 2Clinique Coeur et Vaisseaux, RABAT,
Morocco, 3Polyclinique Bois Bernard, BOIS BERNARD, France, 4Panteleimon
General Hospital, Athens, Greece
Background: Arterial aneurysms (An) are traditionally treated surgically, but more
and more by interventional procedures with a high technical success rate, but some
problems are not solved like protection of aneurysm rupture, endoleaks, stent
thrombosis, collateral branch thrombosis. We used a new concept of stent, the
Multilayer Flow Modulator (MFM*) to treat An. and try to avoid some drawbacks
encountered with endografts.
Methods: This MFM* is a 3 Dimensional braided tube made of several inter-
connected layers without any covering. Our earliest in vitro (theorical simulation),
computerized Fluid dynamics, Molecular Modelization and in vivo tests demonstrated
that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying theears of Interventional Innovation: Novel Therapies and the “Emerging” Device Concepts for 2013
